SS Innovations International, Inc. has obtained regulatory approval for its SSi Mantra surgical robotic system in Colombia, Oman, Sri Lanka, and Kenya, representing a notable expansion of the company's international presence. The approvals enable the company to target what it characterizes as underpenetrated markets with an affordable robotic surgery option. Regulatory clearances were issued by the Instituto Nacional de Vigilancia de Medicamentos y Alimentos in Colombia, the Directorate General of Pharmaceutical Affairs and Drug Control in Oman, the National Medicines Regulatory Authority in Sri Lanka, and the Pharmacy and Poisons Board in Kenya between November 2025 and January 2026.
Dr. Sudhir Srivastava, Chairman and CEO of SS Innovations, emphasized the company's goal to democratize access to state-of-the-art robotic surgery for patients in underserved areas. The company contends that the SSi Mantra's cost benefits, sophisticated technology, distinct features, straightforward training, and user-friendly design make it particularly suitable for these markets. This expansion occurs while SS Innovations continues to navigate regulatory processes in established markets. The company expects the U.S. Food and Drug Administration to finalize its review of the 510(k) premarket notification for the SSi Mantra by mid-2026 and is progressing toward achieving European Union CE marking certification this year.
The SSi Mantra is now authorized in eleven countries, including India, Ecuador, Guatemala, Indonesia, the Philippines, Ukraine, and the United Arab Emirates. As of December 31, 2025, the system had an installed base of 168 units across ten countries and had been utilized in 7,885 cumulative surgeries. These operations encompassed 390 cardiac surgeries and 121 pediatric surgeries. The system has also been employed in more than 150 telesurgeries to date. The SSi Mantra is a modular, multi-arm system featuring an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and compatibility with over 40 different types of robotic endo-surgical instruments. An optional portable console, the SSi MantrAsana Tele Surgeon Console, facilitates telesurgery functionality. Additional details can be found on the company's website at https://ssinnovations.com.
This regulatory expansion is important because it enhances the availability of robotic surgical technology in regions where such advanced medical equipment has traditionally been restricted due to high expenses. By providing a system engineered to be economical and accessible, SS Innovations may help narrow the disparity in surgical care quality between developed and developing nations. The company's emphasis on cost efficiency while maintaining advanced features like telesurgery capability and support for intricate procedures such as cardiac surgery meets a crucial need in global healthcare. As robotic surgery grows more widespread internationally, approvals of this nature could result in enhanced surgical outcomes and expanded procedural alternatives for patients in these countries.
